MedPath

Vizimpro

Brand Name: Vizimpro

Generic Name: Dacomitinib (as monohydrate)

Active
Registration Number

DR-XY48710

Dosage Form

Film-Coated Tablet

Issuance Date

February 13, 2024

Expiry Date

April 25, 2028

Product Information

Philippine FDA product specifications and classification details

Product Specifications

Dosage Strength30 mg
PackagingAlu-PA/Alu/PVC foil blister pack x 10's (Box of 30's) Alu-PA/Alu/PVC foil blister pack x 10's (Box of 10's) as Physician's Samples

Classification

C
Classification
Prescription Drug (RX)
P
Pharmacologic
Antineoplastic Agent (Epidermal Growth Factor Receptor (EGFR) Tyrosine kinase Inhibitor)
A
Application
Monitored Release (MR) (Corrections)
Philippine FDA Classification

Active Ingredients (1)

Complete list of active ingredients in this pharmaceutical product.

Dacomitinib (as monohydrate)Active
Monograph: dacomitinib (as monohydrate)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

MedPath - Medical Intelligence Platform